Whole-Body Hyperthermia in Oncology: Renaissance in the Immunotherapy Era?
- PMID: 37494527
- Bookshelf ID: NBK593469
- DOI: 10.1007/978-3-030-92880-3_8
Whole-Body Hyperthermia in Oncology: Renaissance in the Immunotherapy Era?
Excerpt
A short introduction to the use of whole-body hyperthermia (WBH) in oncology is provided. The main focus is on fever-range whole-body hyperthermia (FRWBH), since various preclinical studies have shown promising results using this approach. However, FRWBH has not been comprehensively investigated in clinical oncology trials. Having provided an overview on the methods to induce WBH, we will summarize preclinical and clinical data on the mode of action of FRWBH. The latter treatment positively affects the tumor micromilieu, especially by decreasing tumor hypoxia. It has the potential to enhance tumor-directed immune reactions and has proven anti-depressive and potential analgesic effects in patients without cancer. These pleiotropic effects align with good tolerability and high acceptability by patients. Given the available evidence, we argue that FRWBH should be investigated as an adjunct to modern cancer treatments in controlled clinical trials.
Copyright 2022, The Author(s).
Sections
References
-
- Urano M, Kahn J, Kenton LA. The effect of cis-diamminedichloroplatinum(II) treatment at elevated temperatures on murine fibrosarcoma, FSa-II. Int J Hyperthermia. 1990;6:563–70. - PubMed
-
- Lassche G, Crezee J, van Herpen CML. Whole-body hyperthermia in combination with systemic therapy in advanced solid malignancies. Crit Rev Oncol Hematol. 2019;139:67–74. - PubMed
-
- Myerson RJ, Singh AK, Bigott HM, et al. Monitoring the effect of mild hyperthermia on tumour hypoxia by Cu-ATSM PET scanning. Int J Hyperthermia. 2006;22:93–115. - PubMed
Publication types
LinkOut - more resources
Full Text Sources